Journal: Journal of Nanobiotechnology

Article Title: CXCR4-engineered fibroblast membrane nanovesicles for Photothermal-enhanced ferroptotic therapy through chemokine-navigated tumor homing

doi: 10.1186/s12951-025-03951-5

Figure Lengend Snippet: Characterization of CXCR4-OE fibroblasts. ( A ) RT-qPCR analysis of CXCR4 expression in murine dermal fibroblasts. ( B ) Western blotting analysis of CXCR4 in fibroblasts and fibroblast membranes. C and D. Representative fluorescence images of fibroblasts stained with FITC-labeled CXCR4 antibody ( C ), and the relative FITC intensity in cells ( D ) ( n = 3). E and F. Representative transwell invasion images of fibroblasts towards different treatments (Control, CXCL12, CXCL12 + LIT-927, CXCL12 + CTR-FbM@IR NPs and CXCL12 + FbM@IR NPs) ( E ), and the number of invaded cells per field ( F ). Data are displayed as mean ± SEM. p < 0.05 (*), p < 0.01 (**) and p < 0.001 (***). CXCR4-OE, CXCR4-overexpressed fibroblasts; CTR, control fibroblasts

Article Snippet: One hour prior to NPs injection, mice received an intraperitoneal injection of the CXCR4 antagonist Plerixafor (3.1 mg/kg, MedChemExpress, USA) or the CXCL12 inhibitor LIT-927 (3.3 mg/kg).

Techniques: Quantitative RT-PCR, Expressing, Western Blot, Fluorescence, Staining, Labeling, Control

Journal: Journal of Nanobiotechnology

Article Title: CXCR4-engineered fibroblast membrane nanovesicles for Photothermal-enhanced ferroptotic therapy through chemokine-navigated tumor homing

doi: 10.1186/s12951-025-03951-5

Figure Lengend Snippet: Cellular internalization and CXCR4-CXCL12 axis-mediated targeting of FbM@IR NPs in tumor spheroids. A and B. Representative CLSM images showing the cellular internalization of FITC-labeled CTR-FbM@IR NPs and FbM@IR NPs into KYSE-30 cells ( A ) and MDA-MB-468 cells ( B ) after 3-hour and 9-hour incubation. C and D. The relative FITC intensity in KYSE-30 ( C ) and MDA-MB-468 cells ( D ). E. ELISA of CXCL12 levels in different cell culture supernatants. F. 3D-merged CLSM images showing the uptake of FITC-labeled FbM@IR NPs, FbM@IR NPs + plerixafor, and CTR-FbM@IR NPs in KYSE-30 spheroids after 24 h of incubation. Data are indicated as mean ± SEM. p < 0.05 (*), p < 0.01 (**) and p < 0.001 (***)

Article Snippet: One hour prior to NPs injection, mice received an intraperitoneal injection of the CXCR4 antagonist Plerixafor (3.1 mg/kg, MedChemExpress, USA) or the CXCL12 inhibitor LIT-927 (3.3 mg/kg).

Techniques: Labeling, Incubation, Enzyme-linked Immunosorbent Assay, Cell Culture

Journal: Journal of Nanobiotechnology

Article Title: CXCR4-engineered fibroblast membrane nanovesicles for Photothermal-enhanced ferroptotic therapy through chemokine-navigated tumor homing

doi: 10.1186/s12951-025-03951-5

Figure Lengend Snippet: Enhanced in vivo tumor targeting of FbM@IR NPs via CXCR4-CXCL12 interaction. A and B. In vivo IR780 distribution in MDA-MB-468 ( A ) and KYSE-30 ( B ) tumor-bearing mice at different time points after i.v. injection of FbM@IR NPs, FbM@IR NPs + Plerixafor, FbM@IR NPs + LIT-927 and CTR-FbM@IR NPs. (Green dashed circles indicate tumor sites). C and D. Ex vivo IR780 distribution in tissues (heart, liver, spleen, lung, kidneys, tumor and lymph nodes) harvested from mice bearing MDA-MB-468 ( C ) and KYSE-30 ( D ) tumor at 48 h after injection of FbM@IR NPs, FbM@IR NPs + Plerixafor, FbM@IR NPs + LIT-927 and CTR-FbM@IR NPs. E and F. Ex vivo IR780 signals of tumors from MDA-MB-468 tumor-bearing mice ( E ) and KYSE-30 tumor-bearing mice (F) ( n = 3). Data are presented as mean ± SEM. p < 0.05 (*), p < 0.01 (**) and p < 0.001 (***)

Article Snippet: One hour prior to NPs injection, mice received an intraperitoneal injection of the CXCR4 antagonist Plerixafor (3.1 mg/kg, MedChemExpress, USA) or the CXCL12 inhibitor LIT-927 (3.3 mg/kg).

Techniques: In Vivo, Injection, Ex Vivo